Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-Tau
Biotech
UCB's tau drug flunks Alzheimer's trial days after Roche's exit
UCB looked past the primary endpoint miss and focused on other results that left it “deeply encouraged” by the trial.
Nick Paul Taylor
Nov 1, 2024 6:01am
Roche tosses out $120M tau prospect, returning rights to UCB
Oct 22, 2024 8:30am
Roche’s Genentech returns Alzheimer’s assets to AC Immune
Jan 22, 2024 8:47am
Janssen moves 1 of 2 AC Immune Alzheimer's vaccines to next step
Nov 30, 2022 10:40am
TauRx plans Alzheimer's approval filing despite phase 3 failings
Oct 6, 2022 8:00am
J&J's Janssen aims for 'sweet spot' of Alzheimer's R&D
Aug 1, 2022 8:00am
